Citation for published version (APA):
Montague, K., Simeoli, R., Sousa-Valente, J., & Malcangio, M. (2018). A novel interaction between CX3CR1 and CCR2 signalling in monocytes constitutes an underlying mechanism for persistent vincristine-induced pain. *Journal of neuroinflammation, 15*(101). https://doi.org/10.1186/s12974-018-1116-6
A novel interaction between CX3CR1 and CCR2 signalling in monocytes constitutes an underlying mechanism for persistent vincristine-induced pain

Karli Montague1, Raffaele Simeoli1,2, Joao Valente3 and Marzia Malcangio1 *

Abstract

Background: A dose-limiting side effect of chemotherapeutic agents such as vincristine (VCR) is neuropathic pain, which is poorly managed at present. Chemokine-mediated immune cell/neuron communication in preclinical VCR-induced pain forms an intriguing basis for the development of analgesics. In a murine VCR model, CX3CR1 receptor-mediated signalling in monocytes/macrophages in the sciatic nerve orchestrates the development of mechanical hypersensitivity (allodynia). CX3CR1-deficient mice however still develop allodynia, albeit delayed; thus, additional underlying mechanisms emerge as VCR accumulates. Whilst both patrolling and inflammatory monocytes express CX3CR1, only inflammatory monocytes express CCR2 receptors. We therefore assessed the role of CCR2 in monocytes in later stages of VCR-induced allodynia.

Methods: Mechanically evoked hypersensitivity was assessed in VCR-treated CCR2- or CX3CR1-deficient mice. In CX3CR1-deficient mice, the CCR2 antagonist, RS-102895, was also administered. Immunohistochemistry and Western blot analysis were employed to determine monocyte/macrophage infiltration into the sciatic nerve as well as neuronal activation in lumbar DRG, whilst flow cytometry was used to characterise monocytes in CX3CR1-deficient mice. In addition, THP-1 cells were used to assess CX3CR1-CCR2 receptor interactions in vitro, with Western blot analysis and ELISA being used to assess expression of CCR2 and proinflammatory cytokines.

Results: We show that CCR2 signalling plays a mechanistic role in allodynia that develops in CX3CR1-deficient mice with increasing VCR exposure. Indeed, the CCR2 antagonist, RS-102895, proves ineffective in mice possessing functional CX3CR1 receptors but reduces VCR-induced allodynia in CX3CR1-deficient mice, in which CCR2 monocytes are elevated by VCR. We suggest that a novel interaction between CX3CR1 and CCR2 receptors in monocytes accounts for the therapeutic effect of RS-102895 in CX3CR1-deficient mice. Indeed, we observe that CCR2, along with its ligand, CCL2, is elevated in the sciatic nerve in CX3CR1-deficient mice, whilst in THP-1 cells (human monocytes), downregulating CX3CR1 upregulates CCR2 expression via p38 MAP kinase signalling. We also show that the CX3CR1-CCR2 interaction in vitro regulates the release of pronociceptive cytokines TNF-α and IL1β.

Conclusions: Our data suggests that CCL2/CCR2 signalling plays a crucial role in VCR-induced allodynia in CX3CR1-deficient mice, which arises as a result of an interaction between CX3CR1 and CCR2 in monocytes.

Keywords: Vincristine, CIPN, CX3CR1, CCL2, CCR2, Monocyte, Macrophage, Sciatic nerve, THP-1, Proinflammatory cytokine

* Correspondence: karli.montague@kcl.ac.uk; marzia.malcangio@kcl.ac.uk
1 Wolfson Centre for Age-Related Diseases, King’s College London, Guy’s Campus, London SE1 1UL, UK
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Chemotherapy-induced painful neuropathy (CIPN) is a dose-limiting side effect of chemotherapeutic drugs, which is poorly managed by analgesics at present [1]. Current treatments for CIPN such as gabapentin and opioids show limited efficacy and engender a host of undesirable side effects such as dizziness and nausea [2, 3]. Indeed, it has been reported that in as many as 40% of patients [4], CIPN results in the premature cessation of chemotherapy and thus jeopardises cancer treatment success. It is therefore essential that novel, more efficacious analgesics are developed and tailored according to different chemotherapeutic agents, which have a broad range of actions. This warrants a deeper understanding of the underlying drug-specific mechanisms of CIPN.

Most chemotherapeutic agents do not cross the blood-brain barrier but are able to penetrate the blood-nerve barrier, where they accumulate in dorsal root ganglia (DRG) and peripheral nerves, causing toxicity that is intensified by the absence of a lymphatic system in the endoneurial compartment [5–7]. Treatments that are currently used for CIPN are predominantly ‘neurocentric’ therapies, which target neuronal response to injury inflicted by chemotherapeutic agents. Compelling evidence from preclinical models of CIPN in recent years however has uncovered the importance of immune cells, such as monocytes/macrophages, and their communication at the endothelial-neuronal interface peripherally [8, 9].

One chemotherapeutic agent associated with neuropathic pain is the vinca alkaloid, vincristine (VCR), used most commonly in the treatment of lymphomas and leukaemias [10]. In a preclinical model of VCR-induced pain, VCR-mediated activation of the endothelium promotes the infiltration of CX3CR1-expressing monocytes into peripheral nerves, where they differentiate into macrophages and activate TRPA1 channels on sensory neurons via the release of reactive oxygen species [9]. An increase in monocyte infiltration into the sciatic nerve is causative of mechanical hypersensitivity (allodynia), as opposed to being an epiphenomenon or downstream event, on the basis that transient depletion of macrophages delays the onset of allodynia until such depletion is ceased and macrophages can populate the sciatic nerve [9]. Communication between monocytes/macrophages and sensory neurons in the periphery has been found to be a key underlying mechanism in preclinical CIPN associated with other chemotherapeutic agents such as paclitaxel. Indeed, depletion of macrophages in the DRG prevents paclitaxel-induced allodynia [11, 12].

Furthermore, inhibition of CX3CR1-mediated activation of macrophages specifically, as well as inhibition of p38 MAPK, a downstream target of CX3CR1 activation, also blocks the development of paclitaxel-induced allodynia [11].

Despite the promise of targeting CX3CR1 receptors in monocytes/macrophages as a prophylaxis for VCR pain, and, indeed, pain associated with other chemotherapeutic agents, a critical caveat remains: CX3CR1-deficient mice still develop VCR-induced allodynia, albeit delayed [9]. It therefore appears that the role of CX3CR1 in monocytes is dynamic and alternative mechanisms emerge with increased exposure to VCR. In this study, we attempt to elucidate such a mechanism that could account for the eventual onset of VCR-induced allodynia in CX3CR1-deficient mice.

Circulating monocytes can, very broadly speaking, exist as two phenotypes—‘patrolling’ or ‘inflammatory’, each of which expresses distinct markers [13]. Patrolling monocytes, characterised by low expression of Ly6C (Ly6C<sup>low</sup>) and high levels of CX3CR1 (CX3CR1<sup>high</sup>), are predominantly associated with homeostatic functions [14]. Inflammatory or ‘classical’ monocytes however express high levels of Ly6C (Ly6C<sup>high</sup>) and relatively low levels of CX3CR1 (CX3CR1<sup>low</sup>). Unlike patrolling monocytes, inflammatory monocytes express the chemokine receptor CCR2 (CCR2<sup>+</sup>). In the sciatic nerve, CCR2 receptor is activated by CCL2, which is expressed by endothelial cells, monocytes/macrophages and sensory neurons [15–17]. Inflammatory monocytes are recruited to sites of injury and inflammation in a CCL2/CCR2-regulated fashion, releasing a multitude of factors, many of which exert pronociceptive functions [18]. It is well-established that neuronal injury, such as that caused by chemotherapy, is accompanied by an increase in macrophages with the inflammatory CCR2<sup>+</sup> phenotype [19, 20].

In this study, we therefore investigate the role of CCL2/CCR2 signalling in inflammatory monocytes/macrophages in VCR-induced allodynia—specifically at later stages of treatment, when the role of CX3CR1 is less pertinent. Given that the CCR2 receptor is also expressed in sensory neurons [17], we also consider the role of CCR2-mediated neuronal activation in order to differentiate between the roles of CCR2 signalling in sensory neurons and monocytes. As well as attempting to elucidate the role of CCR2<sup>+</sup> monocytes/macrophages in VCR-induced allodynia in CX3CR1-deficient mice, we also investigate a potential interaction between CX3CR1 and CCR2 expression in immortalised human monocytes (THP-1 cells). Furthermore, we assess the regulation of pronociceptive cytokines from THP-1 cell downstream of the CX3CR1-CCR2 interaction, which could constitute a potential monocyte-derived signal that mediates monocyte communication with...
nociceptive neurons, which are known to express cytokine receptors \[21\].

**Methods**

**Animals**

Experiments were performed in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 and local animal care and use guidelines. Male and female mice (25–30 g, 12–17 weeks of age) were used. They did not differ with respect to thresholds. Mice were randomly assigned to groups. Each group contained approximately equal numbers of age-matched mice of both sexes.

For Cx3cr1-gfp (green fluorescent protein) mice, an original breeding stock was a kind gift from Steffen Jung (Weizmann Institute of Science, Israel). Cx3cr1-gfp heterozygous mice were generated and genotyped as described \[9\]. For Ccr2-rfp (red fluorescent protein) mice, an original breeding stock was purchased from Jackson Laboratory. Ccr2 disruption/RFP expression was confirmed by PCR using published primers \[22\]. All mice used were generated from a C57Bl/6 background.

**Behavioural testing**

Static mechanical withdrawal thresholds were assessed as described previously \[9\]. Briefly, unrestrained animals were acclimatised for 45 min prior to testing. Calibrated von Frey filaments (0.008–1.4 g) were applied to the plantar surface of the hind paw until they bent and were held for 3 s or until paw withdrawal. A 50% paw withdrawal threshold (in grams) was calculated using the ‘up-down’ method starting with the 0.6-g filament. Three baseline (B) measurements were made prior to treatment, the mean of which is presented. Bilateral measurements were made with no difference in threshold being recorded between left and right (data not shown). Data presented are means of the left and right hind paw thresholds. All tests were conducted blind.

**Drug administration**

Vincristine sulphate (VCR; Sigma-Aldrich) was dissolved in sterile saline. 0.5 mg/kg/day VCR was injected intraperitoneally (i.p.) using a 25-g needle for two 5-day cycles (days 0–4 and 7–11) with a 2-day break as previously described \[9\]. RS-102895 hydrochloride (Sigma), which is a small molecule antagonist of CCR2 receptor belonging to the spiro-piperidine class, was dissolved in dimethyl sulfoxide (DMSO) at 10 mg/ml and diluted in sterile saline; 20 mg/kg/day was injected i.p. for 5 days \[23\] during the second VCR cycle.

**Immunohistochemistry**

Mice, under pentobarbital anaesthesia, were transcardially perfused with saline, followed by 4% paraformaldehyde (PFA). The lumbar enlargement, bilateral L3–5 DRG, and sciatic nerves were excised. Tissue was post-fixed for 4 h and then dehydrated in 30% sucrose in PBS before being embedded in optimum cutting temperature-embedding medium (VWR) and frozen on dry ice. Fifteen-micrometer cryosections were mounted onto Superfrost Plus slides (VWR). Sections were permeabilised for 15 min at room temperature in 0.1% PBS-Trition X-100 (Sigma-Aldrich). Slides were blocked in 0.1% PBS-Trition X-100 + 3% BSA (Sigma-Aldrich) for 1 h at room temperature before being incubated in primary antibody at 4 °C for 16 h. Slides were washed thrice in 0.1% PBS-Trition X-100, before being incubated with the appropriate fluorescently tagged secondary antibody for 1.5 h at room temperature. Slides were washed again and then mounted using FluorSave™ (Merck, UK) and visualised under a Zeiss LSM710 confocal microscope (Zeiss). Five sections per mouse were randomly selected and analysed blind as described previously \[9\].

**Antibodies**

To visualise microglia, anti-lba1 (1:100, WAKO) and anti-rabbit Alexa Fluor 488 (1:1000, Invitrogen) were used. For F4/80 expression, anti-F4/80 (1:400, Abcam) was used followed by anti-rat Alexa 488 or 568 (both 1:1000, Invitrogen). For CCL2 in the sciatic nerve, anti-CCL2 (1:200, Invitrogen) and anti-rabbit Alexa 568 (1:1000, Invitrogen) were used. P-ERK visualisation in DRG was carried out using anti-p-ERK (1:300, Cell Signaling Technology) followed by anti-rabbit Alexa 568 (1 in 1000 Invitrogen). GFP did not require amplification. In all cases, control staining was performed in which no primary antibody was applied.

**Western blot**

Sciatic nerves were fresh-dissected, snap-frozen and stored at −80 °C. Tissue was homogenised in ice-cold RIPA buffer (20 mM tris(hydroxymethyl)aminomethane; 10 mM NaF; 150 mM NaCl; 1% nonyl-phenoxy-polyoxyethanol; 1 mM phenylmethanesulfonyl fluoride; 1 mM Na3VO4 (all Sigma-Aldrich); and 10 mg/ml proteinase inhibitor (Roche)) before being incubated at 4 °C with agitation for 2 h. Samples were centrifuged at 4 °C and 13,000 rpm for 20 min. Supernatant was used for Western blot. For THP-1 cultures, medium was spun at 2000g for 5 min at 4 °C. The pellet was washed, re-suspended in radioimmunoprecipitation assay (RIPA) buffer, vortexed and kept on ice for 30 min, and then spun at 13,000 rpm at 4 °C for 10 min. The supernatant was collected. Protein concentration was determined using the bicinchoninic acid (BCA) protein assay (Pierce). Twenty micrograms of protein per sample was separated on a 15% SDS-PAGE gel and transferred onto a nitrocellulose membrane which was performed according to the manufacturer’s instructions (Bio-Rad, UK). Blots were blocked for 1 h at room temperature in 0.1% TBS-Tween-20 (TBST) + 5%
skimmed milk before being incubated in primary antibody (F4/80), CCL₂ (anti-mouse or human), CCR₂ (anti-mouse or human) (all 1:1000, Abcam) and p-ERK (1:1000 Cell Signaling Technology) at 4 °C overnight along with a loading control (α-tubulin, β-actin both 1:1000, Abcam). After washing in 0.1% TBST, blots were incubated for 1 h at room temperature with HRP-conjugated secondary antibody (1:2000, DAKO). Blots were washed before being developed with SuperSignal® West Femto substrate (Thermo Fisher Scientific). Bands were visualised using BioSpectrum© Imaging and quantified using Quantity One (Bio-Rad, UK).

Flow cytometry
Mice were sacrificed by a rising concentration of CO₂. Peritoneal cavity cells were then elicited by injecting saline into the peritoneal cavity. Lavages were collected and centrifuged at 2400 rpm for 10 min. Pellets were suspended in red phenol-free DMEM (Gibco) supplemented with 10% heat-inactivated foetal bovine serum (HI-FBS), 1% pen/strep and 1% sodium pyruvate. Cells were incubated with conjugated antibodies (CD45.1-Pacific Blue (BioLegend); F4/80-PE (eBioscience); Alexa Fluor® 647 anti-mouse CD192 (CCR₂) Antibody (BioLegend); Ly-6C APC (eBioscience)) on ice for 30 min and then washed twice with PBS containing 1.5% BSA before being re-suspended prior to analysis. Cells were gated and analysed with LSRFortessa™ West Femto substrate (BD bioscience) and FlowJo software (Tree Start).

THP-1 culture
THP-1 cells were a kind gift from Mauro Perretti (Queen Mary, University of London). Cells were cultured in RPMI 1640 with 10% FBS and 2 mM glutamine (Sigma-Aldrich) and maintained in upright T25 tissue culture flasks. For all experiments, cells were cultured in 24-well plates. Cells were transfected using Lipofectamine RNAiMAX (Thermo Fisher Scientific) with CX₃CR₁ siRNA (Insight Biotechnology) or control SignalSilence’siRNA (New England Biolabs) 24 h after seeding, and assays were performed 48 h post-transfection. Efficiency of CX₃CR₁ knockdown was determined using Western blot. In some experiments, cells were pre-treated, 1 h before transfection with siRNA, with SB203580 or PD98059 (both 25 μM, Cambridge Bioscience). For CCL₂ stimulation, cells were treated for 3 h with human recombinant CCL₂ (Cambridge Bioscience) at 10, 50 and 100 ng/ml in HEPES buffer.

Cytokine/chemokine measurement
CCR₂ expression was measured using human chemokine C-C-motif receptor 2 (CCR₂) ELISA Kit (2B Scientific) according to the manufacturer’s instructions. For cytokine expression, a multi-analyte ELISA for proinflammatory cytokines (Qiagen) was performed on culture medium to assess which cytokines were upregulated. ELISA was then performed specifically for TNFα and IL1β (Abcam) according to the manufacturer’s instructions.

Statistics
All data were analysed using SPSS (IBM Analytics). Behavioural data were analysed by repeated measures (RM) two-way ANOVA, followed by Tukey’s test. All other in vivo data were analysed by one-way ANOVA, followed by Tukey’s test. All in vitro data was analysed using Student’s paired t test. All data are shown as mean ± SEM, and data were considered significant when p < 0.05.

Results

CCR₂-deficient mice develop reduced allodynia relative to CCR₂ heterozygous controls at higher cumulative doses of vincristine
In order to establish whether CCR₂ receptor signalling plays a role in VCR-induced allodynia, CCR₂-deficient mice (CCR₂<sup>−/−</sup>RFP/RFP) were treated with two 5-day cycles of VCR [9, 24]. In the first cycle, they were found to develop significant VCR-induced allostery to the same severity and within the same time frame as heterozygous (CCR₂<sup>+/−</sup>RFP), littermate controls (Fig. 1a). Specifically, within 24 h of the first VCR dose and throughout the first treatment cycle, mechanical withdrawal thresholds of both CCR₂-deficient and heterozygous mice were significantly reduced relative to saline-treated mice. Indeed, there was no difference in threshold between VCR-treated CCR₂-deficient and heterozygous mice throughout the first VCR cycle (days 0–4). During the second cycle of VCR however, CCR₂-deficient mice had significantly higher thresholds, thus reduced allodynia, relative to heterozygous controls (Fig. 1a).

VCR-induced monocyte infiltration in peripheral nerve tissue is significantly reduced in CCR₂-deficient mice during the second VCR cycle
We initially confirmed that VCR administration did not cause a measurable microglial response (Additional file 1: Figure S1A, B), before focussing our attention on the sciatic nerve, where VCR accumulates and mechanisms underlying preclinical VCR pain are most pertinent [9]. In CCR₂ heterozygous mice, the elevation of macrophages in the sciatic nerve occurred to the same degree during both the first and second cycles of VCR treatment as demonstrated by immunohistochemical (Fig. 1b, c) and Western blot detection (Fig. 1d, e) of the macrophage marker F4/80. In CCR₂-deficient mice however, when allodynia was significantly reduced during the second cycle relative to the first cycle, we observed that F4/80 expression was also significantly reduced in the sciatic nerve relative to the first VCR cycle (Fig. 1b–e).
Treatment of CX3CR1 heterozygous mice with a CCR2 antagonist does not reduce VCR-induced allodynia or monocyte infiltration in the sciatic nerve

In light of the apparent involvement of the CCR2 receptor in VCR allodynia during the second VCR cycle, we wanted to establish if treatment with a CCR2 antagonist on VCR-induced allodynia mirrors genetic deficiency, as well as identify whether CCR2 does indeed play a role in VCR-induced allodynia in CX3CR1-deficient mice during the second cycle. To address the first of these questions, we began by administering the CCR2 antagonist RS-102895 during the second VCR cycle to CX3CR1 heterozygous mice.
heterozygous mice, which possess functional CX3CR1. Our rationale for therapeutic (VCR cycle 2) as opposed to prophylactic (VCR cycle 1) dosing was derived not only from the apparent effect of CCR2 deficiency on VCR-induced allodynia during the second VCR cycle specifically but also from previous observations that whilst the development of VCR-induced allodynia is orchestrated by CX3CR1 signalling in monocytes, other mechanisms appear to regulate allodynia during the second VCR cycle [9]. Indeed, prophylactic treatment with RS-102895 during the first VCR cycle had no effect on withdrawal thresholds (Additional file 1: Figure S2). However, we found that when CX3CR1 heterozygous mice were given RS-102895 during the second VCR cycle, there was still no change in VCR-induced allodynia (Additional file 1: Figure S3A). Concurrently, VCR-induced monocyte/macrophage infiltration into the sciatic nerve was also unaltered by administration of RS-102895 during the second VCR cycle (Additional file 1: Figure S3B, C).

**Treatment of CX3CR1-deficient mice with a CCR2 antagonist significantly reduces VCR-induced allodynia and monocyte infiltration into peripheral nervous tissue**

Although our data so far suggests that CCR2 antagonism during the second VCR cycle is not necessarily therapeutic in mice possessing functional CX3CR1 receptor, this does not rule out a role for CCR2-mediated signalling in VCR-induced allodynia that has been observed in CX3CR1-deficient mice at later stages of treatment [9]. We therefore treated CX3CR1-deficient (CX3CR1<sup>GFP/GFP</sup>) mice with two cycles of VCR in the presence of RS-102895 (or vehicle) during the second VCR cycle, when allodynia manifests in CX3CR1-deficient mice [9]. As observed previously, CX3CR1-deficient mice displayed a delayed onset of allodynia in response to VCR treatment relative to heterozygous littermates. Whilst CX3CR1 heterozygous mice developed significant allodynia within 24 h of the first VCR dose (Additional file 1: Figure S3A), mechanical thresholds only dropped significantly in CX3CR1-deficient mice relative to saline-treated controls at the end of the first VCR cycle (Fig. 2a). In addition, dissimilar to the results obtained in CX3CR1 heterozygous mice, systemic treatment of CX3CR1-deficient mice with RS-102895 during the second VCR cycle significantly reduced VCR-induced allodynia (Fig. 2a). Although withdrawal thresholds in CX3CR1-deficient mice treated with RS-102895 alongside VCR were still significantly lower than baseline levels, a significant increase relative to CX3CR1-deficient mice treated with VCR alone was observed within 24 h of the first RS-102895 dose and persisted throughout the second VCR cycle. Crucially, administration of RS-102895 in all saline-treated mice did not alter mechanical thresholds (Fig. 2a, Additional file 1: Figure S3). This data exposes a potential role for CCL2/R<sub>2</sub> signalling in VCR-induced allodynia in CX3CR1-deficient mice during the second cycle specifically.

Given that RS-102895 significantly reduced VCR-induced allodynia in CX3CR1-deficient mice during the second VCR cycle, we assessed whether it also resulted in a simultaneous reduction in VCR-induced monocyte infiltration into the sciatic nerve. In CX3CR1 heterozygous mice, RS-102985 administration during the second VCR cycle did not significantly reduce VCR-induced monocyte infiltration into the sciatic nerve, as demonstrated by immunohistochemistry (Fig. 2b, e) and Western blot analysis (Fig. 2d, e) of F4/80. However, the administration of RS-102895 to VCR-treated CX3CR1-deficient mice did indeed result in a significant reduction in macrophage number in the sciatic nerve (Fig. 2b–e). This suggests that the mechanism by which RS-102895 significantly reduces VCR-induced allodynia in CX3CR1-deficient mice is, at least in part, regulated by CCR2 signalling in, or CCR2-mediated recruitment of, monocytes/macrophages in peripheral nerves. Furthermore, the reduction in VCR-induced allodynia and monocyte infiltration that accompanied the administration of RS-102895 to CX3CR1-deficient mice specifically is suggestive of changes in CCR2 expression and/or activity as a result of loss of CX3CR1 in monocytes/macrophages in the periphery.

**The reduction in VCR-induced allodynia in CX3CR1-deficient mice treated with RS-102895 does not require sensory neuron CCR2 receptors**

Unlike CX3CR1, which is predominantly expressed by monocytes/macrophages, CCR2 is additionally expressed on sensory neurons [16, 17]. To investigate the potential contribution of CCR2 signalling in sensory neurons to the reduction in VCR-induced allodynia observed in RS-102895-treated CX3CR1-deficient mice, we considered the effect of RS-102895 on CCR2-mediated neuronal activation. In both CX3CR1-deficient and heterozygous mice, two cycles of VCR administration resulted in the upregulation of phospho-p44/42 MAPK2 (p-ERK2), a marker for neuronal activation and downstream target of CCR2 signalling [25, 26] as demonstrated by both immunohistochemistry (Fig. 3a, b) and Western blot analysis in lumbar DRG (Fig. 3c, d). Administration of RS-102895 for the duration of the second VCR cycle however resulted in a significant reduction of p-ERK2 in lumbar DRG from both CX3CR1-deficient and heterozygous mice (Fig. 3a–d) suggesting that the effect of RS-102895 on VCR-induced elevation of p-ERK2 did not differ between genotypes. Crucially, at day 14 (3 days after treatment cessation), VCR-treated CX3CR1-deficient mice that had received RS-102895 still had significantly
RS-102895 significantly reduces VCR-induced allodynia and monocyte infiltration in the sciatic nerve in CX3CR1-deficient mice. a CX3CR1 knockout (GFP/GFP) mice were treated with two VCR cycles alongside the CCR2 antagonist RS-102985, or vehicle, during the VCR cycle 2. CX3CR1(GFP/GFP) mice developed VCR-induced allodynia at the end of cycle 1 (day 4) as previously reported. Data expressed as 50% paw withdrawal thresholds (mean ± SEM, n = 6–9 mice per group). In VCR/RS-102895-treated CX3CR1(GFP/GFP) mice (red trace), withdrawal thresholds increased significantly relative to VCR/vehicle-treated CX3CR1(GFP/GFP) mice (blue) within 24 h of the first antagonist dose. *p < 0.05, two-way RM ANOVA, Tukey’s test.

b Representative images of macrophages (F4/80, red) in sciatic nerve longitudinal sections at day 11 from VCR-treated CX3CR1(GFP/GFP) and CX3CR1(+/GFP) mice. Scale bar = 50 μm.

c Quantification of F4/80+ profiles per 10^4 μm^2 in the sciatic nerve at day 11 (mean ± SEM, n = 4 mice per group; five fields of view were quantified for each mouse). RS-102985 significantly reduces VCR-induced elevation of F4/80+ profiles in sciatic nerves from CX3CR1(GFP/GFP) mice. NS not significant, **p < 0.01, one-way ANOVA, Tukey’s test.

d Representative blot of F4/80 (130 kDa) and α-tubulin (50 kDa) in sciatic nerve homogenates obtained from CX3CR1(+/GFP) and CX3CR1(GFP/GFP) mice at day 11. e Quantification of F4/80 band density normalised to α-tubulin (mean ± SEM, n = 3). RS-102985 significantly reduces VCR-associated infiltration into sciatic nerves obtained from CX3CR1(GFP/GFP) mice. NS not significant, *p < 0.05, one-way ANOVA, post hoc Tukey’s test.
Reduction in VCR-induced allodynia by RS-102985 does not require neuronal activation.

**a** Representative images of GFP (macrophages, CX3CR1, green) and p-ERK (neuronal activation, red) in L4 DRG taken from VCR-treated CX3CR1^GFP and CX3CR1^GFP/GFP mice at treatment day 11. Mice were co-treated with RS-102985 or vehicle. Scale bar, 50 μm.

**b** Quantification of p-ERK+ profiles per mm^2 at day 11 (mean ± SEM, n = 4 mice per group). VCR induces neuronal activation, which is significantly reduced by RS-102895 at day 11. ***p < 0.001, one-way ANOVA, Tukey’s test.

**c** Representative blot of p-ERK2 (42 kDa) and α-tubulin (50 kDa) in L3–L5 DRG homogenates obtained from CX3CR1^GFP and CX3CR1^GFP/GFP mice at treatment day 11. **d** Quantification of p-ERK2 band density normalised to α-tubulin (mean ± SEM, n = 3). In both genotypes, RS-102895 administration significantly reduces VCR-induced p-ERK2 expression in L3–L5 DRG. *p < 0.05, one-way ANOVA, Tukey’s test.

**e** 50% paw withdrawal thresholds (g) at study day 11 for VCR/RS-102985-treated CX3CR1^GFP/GFP mice relative to those treated with VCR and vehicle (mean ± SEM, n = 6–9 mice per group). Prior RS-102985 treatment does not continue to prevent p-ERK activation in either genotype. Scale bar = 50 μm.

**f** Representative blot and quantification of p-ERK2 and α-tubulin in bilateral L3–L5 DRG homogenates. In both genotypes, DRG from VCR/RS-102895-treated mice express similar normalised p-ERK2 expression to VCR/vehicle-treated mice (mean ± SEM, n = 3).

---

Fig. 3 Reduction in VCR-induced allodynia by RS-102985 does not require neuronal activation. **a** Representative images of GFP (macrophages, CX3CR1, green) and p-ERK (neuronal activation, red) in L4 DRG taken from VCR-treated CX3CR1^GFP and CX3CR1^GFP/GFP mice at treatment day 11. Mice were co-treated with RS-102985 or vehicle. Scale bar, 50 μm. **b** Quantification of p-ERK+ profiles per mm^2 at day 11 (mean ± SEM, n = 4 mice per group). VCR induces neuronal activation, which is significantly reduced by RS-102895 at day 11. ***p < 0.001, one-way ANOVA, Tukey’s test. **c** Representative blot of p-ERK2 (42 kDa) and α-tubulin (50 kDa) in L3–L5 DRG homogenates obtained from CX3CR1^GFP and CX3CR1^GFP/GFP mice at treatment day 11. **d** Quantification of p-ERK2 band density normalised to α-tubulin (mean ± SEM, n = 3). In both genotypes, RS-102895 administration significantly reduces VCR-induced p-ERK2 expression in L3–L5 DRG. *p < 0.05, one-way ANOVA, Tukey’s test. **e** Withdrawal thresholds at days 14–16 remain significantly higher in VCR/RS-102985-treated CX3CR1^GFP/GFP mice relative to those treated with VCR and vehicle (mean ± SEM, n = 6–9 mice per group). *p < 0.05, two-way RM ANOVA, Tukey’s test. **f** Representative images of GFP (macrophages) and p-ERK (red) in L4 DRG taken from CX3CR1^GFP and CX3CR1^GFP/GFP mice at day 14. Prior RS-102985 treatment does not continue to prevent p-ERK activation in either genotype. Scale bar = 50 μm. **g** Quantification of p-ERK+ profiles per mm^2 at day 14 (mean ± SEM, n = 4 mice per group). NS not significant. **h** Representative blot and quantification of p-ERK2 and α-tubulin in bilateral L3–L5 DRG homogenates. In both genotypes, DRG from VCR/RS-102895-treated mice express similar normalised p-ERK2 expression to VCR/vehicle-treated mice (mean ± SEM, n = 3).
reduced allodynia relative to CX₃CR₁ heterozygous mice (Fig. 3e). However, p-ERK2 activation was observed in lumbar DRG at this time point regardless of genotype, as demonstrated by immunohistochemistry (Fig. 3f, g) and Western blot analysis (Fig. 3h). This could suggest that the reduction in VCR-associated allodynia in RS-102895-treated CX₃CR1-deficient mice is not entirely dependent on the diminution of sensory neuronal activation via CCR₂ receptor antagonism and could therefore also be regulated by CCR₂ signalling elsewhere, such as that present in monocytes/macrophages.

This data also indicates that it is less likely that the absence of effect of RS-102895 in CX₃CR₁ heterozygous mice was due to lack of bioavailability. Activation of p-ERK is a well-established downstream event of CCR₂ receptor activation; thus, the fact that VCR-induced p-ERK activation was only reduced when RS-102895 was administered and not at day 14, at which point treatment was terminated (Fig. 3e–g), provides us with a measureable outcome of RS-102895 bioavailability and target engagement.

**CCL₂/R₂ expression is altered in macrophages in the sciatic nerve of CX₃CR₁-deficient mice**

Given the effect of RS-102895 treatment on CX₃CR₁-deficient mice specifically and that CX₃CR₁ deficiency is associated with CCL₂ upregulation in phagocytic cells [27, 28], we went on to examine CCL₂ expression in the sciatic nerve of CX₃CR₁-deficient mice. Western blot analysis of CCL₂ expression in sciatic nerve homogenates from CX₃CR₁-deficient and heterozygous mice that had been treated with saline only demonstrated that CCL₂ elevation in the sciatic nerve accompanied CX₃CR₁ deficiency (Fig. 4a, b). In addition, we found that two VCR cycles increased CCL₂ expression in the sciatic nerve of both CX₃CR₁-deficient and heterozygous mice (Fig. 4a, b). Immunohistochemical analysis of GFP⁺ (macrophages) and CCL₂⁺ profiles in the sciatic nerve suggested that increases in CCL₂ in the sciatic nerve in CX₃CR₁-deficient mice and in both genotypes in response to VCR treatment were, at least in part, a result of an increase of CCL₂ in macrophages (Fig. 4c, d). In order to confirm that the results obtained were not a misrepresentation afforded by potential antibody artifacts, we confirmed that CCL₂ could not be detected in sciatic nerve tissue from CCL₂-deficient mice (data not shown).

**CX₃CR₁ deficiency is associated with high CCR₂ monocyte infiltration in peripheral nerves**

Our data to this point demonstrates that (i) treatment with a CCR₂ antagonist (RS-102895) reduces VCR-induced allodynia and monocyte/macrophage infiltration in sciatic nerves in CX₃CR₁-deficient mice during cycle two specifically and (ii) VCR induces CCL₂ elevation in monocytes/macrophages. However, whether VCR allodynia is associated with peripheral nerve infiltration of CCR₂-expressing monocytes, which provide a cellular target for RS-102895, has yet to be determined. We therefore considered evaluating monocytes/macrophages in peripheral nerve tissue specifically; however, the yield obtained during isolation was suboptimal for reliable characterisation. We therefore used peritoneal lavages as a surrogate source of monocytes [9]. Importantly, we confirmed that CCR₂ receptor is indeed detectable in both control and lipopolysaccharide (LPS)-stimulated peritoneal cells using both Western blot and FACS analysis of Ly6C⁺ CCR₂ cells (Additional file 1: Figure S4).

In light of our evidence that CCR₂ receptor is detectable, we measured peritoneal CCR₂ monocytes (F4/80⁻ cells) in CX₃CR₁-deficient and heterozygous mice following two cycles of VCR using FACS analysis. We observed that in both genotypes, two cycles of VCR treatment significantly increased F4/80⁺ Ly6C⁺ CCR₂ cells relative to saline-treated controls (Fig. 4e, f). Furthermore, the number of F4/80⁺ Ly6C⁺ CCR₂ cells in VCR-treated CX₃CR₁-deficient mice was significantly greater than that measured in heterozygous controls, indicating that CX₃CR₁ deficiency was associated with an increase of CCR₂⁺ monocyte numbers in vivo. Critically, treatment with RS-102895 during the second VCR cycle significantly reduced the number of F4/80⁺ Ly6C⁺ CCR₂ cells to a greater extent in CX₃CR₁-deficient mice (Fig. 4e, f). Taken together, this data is suggestive of an interaction between CX₃CR₁ and CCR₂ receptors in monocytes.

**Knocking down CX₃CR₁ expression in a human monocyte cell line results in an increase in CCL₂/R₂ expression via p38 MAPK signalling**

In order to investigate whether CX₃CR₁ regulates CCR₂ expression in monocytes, we knocked down CX₃CR₁ expression using siRNA in the human monocyte THP-1 cell line, which resulted in an approximately 80% reduction in CX₃CR₁ expression (Additional file 1: Figure S5A). As shown previously [26], we confirmed that downregulation of the CX₃CR₁ receptor in monocytes is accompanied by an increase in CCL₂ expression (Fig. 5a). In addition, however, a significant increase in CCR₂ expression was also observed, with CX₃CR₁ siRNA-transfected THP-1 cells expressing significantly higher levels of CCR₂ relative to those transfected with control siRNA (Fig. 5b, Additional file 1: Figure S4B). Furthermore, when cells were pre-treated with the p38 MAP kinase inhibitor, SB203580, downregulation of CX₃CR₁ (which is unaffected by SB203580 administration (Additional file 1: Figure S5C)) did not result in an increase in CCR₂ expression (Fig. 5c). When cells were pre-treated with the MAPK/ERK kinase inhibitor, PD98059, however, CX₃CR₁ downregulation
resulted in an increase in CCR2 expression (Fig. 5c). Taken together, these data suggest that downregulation of CX3CR1 in THP-1 cells in vitro results in upregulation of CCR2 receptor via p38 MAP Kinase signalling.

**Downregulation of CX3CR1 regulates proinflammatory cytokine levels in vitro**

In order to begin to identify a mechanism by which an interaction between CX3CR1 and CCR2 in monocytes could potentially result in mechanical allodynia, we then went on to establish whether this interaction regulates the release of pronociceptive mediators. Indeed, downregulation of CX3CR1 resulted in a significant increase in the basal release of the proinflammatory cytokines TNF-α and IL1β to the same extent as stimulation of non-transfected THP-1 cells with 10 ng/ml CCL2 (Fig. 5d, e). Furthermore, release of TNF-α and IL1β, following stimulation with higher doses of CCL2 (50 and 100 ng/ml), was not significantly higher than those observed following CX3CR1 receptor downregulation alone (Fig. 5d, e).

In short, our THP-1 cell data demonstrates the presence of a novel interaction between CX3CR1 and CCR2 receptor expression, which is mediated by p38 MAP kinase signalling. In addition, it demonstrates that the CX3CR1-CCR2 interaction in vitro regulates the release of pronociceptive cytokines, thus providing a potential means by which monocytes could communicate...
with sensory neurons in the mediation of allostynia in CX3CR1-deficient mice during the second VCR cycle.

**Discussion**

Chemotherapy-induced painful neuropathy (CIPN) is a dose-limiting side effect that jeopardises the success of cancer therapy [1]. The need for novel, more effective pain therapies, which necessitates a deeper understanding of the underlying mechanisms, is therefore profound. Different chemotherapeutic agents are likely to induce CIPN via a range of mechanisms, and thus, future therapies are likely to be most effective if they are tailored for specific cancer treatments.
In this study, we elucidate a mechanism underlying pain associated with vincristine (VCR) treatment and present evidence to suggest that CCR2 receptor signalling in monocytes infiltrating the sciatic nerve plays a role in VCR-induced allodynia in CX3CR1-deficient mice during the second cycle specifically. We begin to elucidate a novel interaction between CX3C1R1 and CCR2 in monocytes and demonstrate in vitro that it regulates the release of proinflammatory cytokines that have been previously shown to modulate neuronal mechanisms underlying chronic pain [23, 29].

We initially show that in CCR2-deficient mice, VCR-induced allodynia and concurrent monocyte infiltration into the sciatic nerve develop to the same severity and within the same time frame as CCR2 heterozygous littermates but are both significantly reduced during the second VCR cycle. Our findings from CCR2-deficient mice however is not enough to confirm a role for CCR2 signalling in monocytes per se in VCR-induced pain. CCR2 mediates the egression of monocytes from the bone marrow into the bloodstream where they survey the environment surrounding tissue [30, 31]. It is therefore plausible that the reduction in allodynia that we observe is a result of prevention of monocyte egression as opposed to CCR2 signalling in macrophages in the sciatic nerve specifically. Indeed, pharmacological inhibition of CCR2 affords a very different scenario biologically to CCR2 deficiency and as such is accompanied by different behavioural and biological manifestations. Specifically, when we administered the CCR2 antagonist RS-102895 to VCR-treated mice during the second cycle, we observed that neither VCR-induced allodynia nor monocyte infiltration into the sciatic nerve was reduced.

Our pivotal observation however was that RS-102895 administration during the second VCR cycle did significantly reduce established VCR-induced allodynia and monocyte infiltration into the sciatic nerve of CX3CR1-deficient mice. Indeed, in keeping with this, CCR2 receptor inhibition in CX3CR1-deficient mice specifically has also been found to be protective in other pathological conditions such as macular degeneration [27].

In addition we found that the (i) VCR-induced increase in CCR2 monocytes in the peritoneal cavity was exacerbated in CX3CR1-deficient mice and (ii) RS-102895 treatment significantly reduced the VCR-induced increase in CCR2+ monocytes in CX3CR1-deficient mice specifically. Taken together, these data are suggestive of an interaction between CX3C1R1/CX3CR1 and CCL2/CCR2 chemokine/receptor systems in monocytes that could underlie the onset of VCR-induced allodynia in CX3CR1-deficient mice.

Interactions between CX3CR1 receptor and CCL2 have been reported previously in other contexts. Indeed, in addition to our observation that CCL2 is elevated in the sciatic nerve of CX3CR1-deficient mice, the expression of CCL2 has also been shown to be elevated in mononuclear phagocytes in the retina in CX3CR1-deficient mice [27]. Here, we present novel evidence that CCR2 receptor expression is also altered downstream of CX3CR1 downregulation in vitro. Specifically, when we downregulated CX3CR1 expression in immortalised human monocyte THP-1 cells, we observed a significant upregulation in both CCL2 and CCR2. Pharmacological inhibition of p38 MAPK but not MEK prevented this effect, and thus, we suggest that downregulation of CX3CR1 results in upregulation of the CCR2 receptor via p38 MAPK signalling.

As well as CX3CR1-mediated regulation or CCL2 and CCR2 expression in monocytes, the converse interaction has also been observed previously. Specifically, CCL2 stimulation of monocytes has been found to increase CX3CR1 receptor expression at monocyte membranes, most likely due to the stimulation of receptor translocation from intracellular stores as opposed to the stimulation of de novo expression [31]. This regulation has been shown to occur via CCR2-mediated activation of p38 MAPK, with pharmacological inhibition of p38 MAPK, attenuating the effect [31]. This data, in conjunction with the data presented in our study, suggests that the interaction between CX3CR1 and CCR2 receptors in monocytes is reciprocal and that expression of CX3CR1 and CCR2 is mutually regulated.

As well as CX3CR1 deficiency being associated with an increase in CCL2/CCR2 expression, VCR treatment was also found to increase CCL2. Elevated CCL2/CCR2 signalling in CX3CR1-deficient mice under basal conditions could explain the efficacy of RS-102895. The basal elevation of CCL2/CCR2 signalling alone in CX3CR1-deficient mice is not likely to be sufficient to cause allodynia as withdrawal thresholds did not vary between salinetreated CX3CR1-deficient and heterozygous mice. However, the potentially additive effect of CX3CR1 deficiency and two cycles of VCR on CCL2/CCR2 expression could indeed result in susceptibility to hypersensitivity. This could account for the onset of allodynia in CX3CR1-deficient mice at later stages of VCR treatment and the therapeutic benefit of CCR2 inhibition, which could also be attributed to increases in CCR2+ monocytes found in CX3CR1-deficient mice. Indeed, CCL2/R2 signalling in sensory neurons is a well-established mediator of pain.

The elevation of CCR2+ monocytes and CCL2 expression in sciatic nerves that we observe in CX3CR1-deficient mice, in addition to VCR-induced increases in CCL2, is likely to cumulatively increase activity of the CCL2/CCR2 signalling axis in sensory neurons, thus activating pain pathways [32–34].

Whereas CX3CR1 is mainly found in monocytes/macrophages, the CCR2 receptor is expressed by other cell types. Elucidating the role of CCR2 signalling in monocytes/macrophages specifically is therefore a more
intricate process than unravelling the role of CX₃CR₁ signalling in monocytes. For instance, the CCR₂ receptor is also expressed in sensory neurons [17]. To attribute at least part of our observed effect of RS-102895 in CX₃CR₁-deficient mice to inhibition of CCR₂ in monocytes specifically, we needed to consider a role for CCR₂ inhibition in sensory neurons. A well-established downstream target of CCR₂ signalling in neurons is p-ERK activation, which is associated with noxious activation of sensory neurons [25]. At the end of two cycles of VCR treatment, we found that p-ERK2 is elevated in DRG neurons in both CX₃CR₁-deficient and heterozygous mice. However, RS-102895 reduced VCR-associated p-ERK2 expression to the same extent in both genotypes despite the fact that allodynia is significantly reduced in CX₃CR₁-deficient mice. Although this does not rule out a role for CCR2-mediated neuronal activation in VCR alldynia, since thresholds observed in CX₃CR₁-deficient mice are still considered to be allodynic, it could suggest that other CCR₂-mediated mechanisms are just as pivotal in regulating the severity of alldynia. Another key observation was that after the treatment was terminated, p-ERK2 activation in VCR-treated mice that also received RS-102895 was no longer reduced, regardless of the genotype. Crucially, however, alldynia was still significantly reduced in CX₃CR₁-deficient mice, despite measureable p-ERK2 activation. This could suggest one of two things: either the reduction in VCR alldynia in RS-102895-treated CX₃CR₁-deficient mice does not depend on the effect on neuronal activation or the dominant underlying mechanisms regulating VCR alldynia change as VCR pain evolves into ongoing after VCR treatment is terminated. Regardless of the explanation, however, our data suggests that there is scope for CCR₂-mediated mechanisms that do not only require activation of CCR₂ in sensory neurons to regulate VCR-associated allodynia in CX₃CR₁-deficient mice. CCR₂ signalling in monocytes could be a candidate for such a mechanism.

Indeed, our final, crucial observation was that downregulation of CX₃CR₁ in human monocytes in vitro regulated basal release of the proinflammatory cytokines TNFα and IL1β. It is well-established that both TNFα and IL1β are pronociceptive [29, 35], and thus, this provides us with a crucial link between the CX₃CR₁-CCR₂ interaction in monocytes and noxious signalling. Indeed, we confirmed that CCL₂ stimulation of THP-1 cells also results in TNFα and IL1β release and observed that both CCL₂ and CCR₂ are elevated in THP-1 cells when CX₃CR₁ is downregulated thus suggesting that downregulation of CX₃CR₁ results in the release of proinflammatory cytokines through heightened CCL₂/CCR₂ signalling. Our data suggests the presence of a novel interaction between CX₃CR₁ and CCR₂ receptors, which regulates the release of monocyte-derived signals that mediate communication between monocytes and nociceptive neurons (Fig. 6). Critically, in vivo, we observe that under basal conditions, CX₃CR₁ deficiency is associated with an increase in CCL₂ in macrophages in the sciatic nerve and that VCR treatment increases CCL₂ expression further, which would cumulatively result in the release of pronociceptive cytokines and thus mediate pain signalling.

Conclusions

Our data provides exciting evidence for a novel role of CCR₂ receptor signalling in monocytes in VCR-associated alldynia in CX₃CR₁-deficient mice, which is likely to manifest as a result of an interaction between CX₃CR₁ and CCR₂ expression in monocytes in the periphery. Identification of this interaction could thus uncover a new therapeutic target for longer-term treatment of vincristine pain.

---

**Fig. 6** CCL₂/CCR₂ signalling in monocytes/macrophages plays a crucial role in VCR pain in CX₃CR₁-deficient mice. (1) Downregulation or silencing of CX₃CR₁ in monocytes results in upregulation of CCR₂ via p38 MAP kinase signalling. (2) Monocytes infiltrate through the endothelium into peripheral nerve tissue in a CCL₂/CCR₂-dependent manner. (3) Cytokines such as TNFα and IL1β are released downstream of CCR₂ signalling in monocytes. (4) TRPV₁ channels mediate noxious signalling following TNFα receptor activation in sensory neurons.
Additional file

**Additional file 1**: Table S1. Antibodies used for immunohistochemistry. Table S2. Antibodies used for Western blot analysis. Figure S1. No microglial response is detectable in VCR-treated CCR, heterozygous or knockout mice. Figure S2. Prophylactic treatment of CCL2 c57BL/6j heterozygous mice with RS-102895 does not affect the onset or severity of allodynia in cycle 1. Figure S3. Treatment with RS-102895 does not reduce VCR-associated allodynia in C57BL/6j mice. Figure S4. Pentoneal monocytes/macrophages express CCR2 under basal conditions. Figure S5. Transfection of THP-1 cells with CCL2 siRNA downregulates CCL2 expression and upregulates CCR2 expression via p39 MAP kinase. (DOX 960 kb)

**Abbreviations**

CCL2: C-C motif chemokine ligand 2; CCR2: C-C chemokine receptor type 2; CIPN: Chemotherapy-induced painful neuropathy; CXC1CL1: C-X-C motif chemokine ligand 1; CX3CR1: C-X3-C motifchemokine receptor 1; EL1β: Interleukin 1-beta; MAPK/ERK kinase; p38 MAPK; p38 mitogen-activated protein kinase; p-Erk1/2: Phospho-p44/42 MAPK (Erk1/2); siRNA: Short interfering ribonucleic acid; THP-1: Tamrin-Horsfall protein 1; TNFα: Tumour necrosis factor Alpha; TRPV1: Transient receptor potential cation channel subfamily V member 1; VCR: Vincristine

**Acknowledgements**

We thank Thomas Pitcher for the technical assistance.

**Funding**

KM is supported by the Medical Research Council, UK (MR/M023893/1).

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on a reasonable request.

**Authors’ contributions**

KM and MM designed and interpreted the experiments. KM and MM wrote the manuscript. KM, RS, and JV performed the experiments. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

N/A

**Consent for publication**

N/A

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Wolfson Centre for Age-Related Diseases, King’s College London, Guy’s Campus, London SE1 1UL, UK. 2Infectology and Clinical Trials Research Department, Bambino Gesu’ Children’s Hospital, IRCCS, Rome, Italy. 3Vascular Biology and Inflammation Section, Cardiovascular School of Medicine & Science, British Heart Foundation Centre of Excellence, King’s College London, Franklin-Wilkins Building, 150 Stamford Street, King’s College London, London SE1 9NH, UK.

Received: 17 November 2017 Accepted: 5 March 2018

Published online: 06 April 2018

**References**

1. Serery M, Currie GL, Sena ES, Rammarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70. https://doi.org/10.1016/j.pain.2014.09.020.

2. Dougherty PM, Kata JP, Burton AV, Wu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manag. 2007;33(2):166–79.

3. Bloodworth D. Issues in opioid management. Am J Phys Med Rehabil. 2005; 84(1 Suppl 3):S42–S55.

4. Bennett BK, Park SB, Lin CS, Friedlander ML, Kienan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012;20(11):2959–67.

5. Cavalletti G, Nicolini G, Marmiroli P. Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci. 2008;13:3506–24.

6. Balayssac D, Cayre A, Audith N, Boudou S, Perault-Lorca F, Gillet JP, Maublant J, Eschaler A, Coudere F. Patterns of p-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. J Peripher Nerv Syst. 2005;10(3):301–10.

7. Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2003;3(1):86–92.

8. Montague K, Malcangio M. The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain. J Neurochem. 2017; 141(4):520–31.

9. Old EA, Nadkarni S, Grist J, Gentry C, Bevan S, Kim KW, Mogg AJ, Perretti M, Malcangio M. Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest. 2014;124(5):2023–36.

10. Mora E, Lavoie Smith EM, Donohoe C, Hertz DL. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res. 2016; 6(11):2416–30.

11. Huang ZZ, Li D, Liu CC, Cui Y, Zhu HQ, Zhang WW, Li YY, Xin WJ. CXCCL1-mediated macrophage activation contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathy. Brain Behav Immun. 2014;40:155–65.

12. Zhang H, Li Y, de Carvalho-Barbosa M, Kavelaars A, Heijnen CJ, Albrecht PJ, Dougherty PM. Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy. J Pain. 2016;17(7):775–86.

13. Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr Opin Hematol. 2010;17(1):53–9.

14. Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrena G, Hedrick CC, Cook HT, Diebold S, Geissmann F. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell. 2013;153(2):362–75.

15. Langhert KA, Von Zee CL, Stubbs Jr EB. Tumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endothelial cells. ASN Neuro. 2013;3(1):e000104.

16. Sierra-Filardi E, et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCL2-receptor-dependent gene expression profile. J Immunol. 2014;192(8):3875–87.

17. Zhang H, Boyette-Davis JA, Kosturakis AK, Li Y, Yoon SY, Walters ET, Dougherty PM. Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. J Pain. 2013;14(10):1031–44.

18. Ingersoll MA, Platt AM, Porteaux S, Randolph GJ. Monocyte trafficking in acute and chronic inflammation. Trends Immunol. 2011;32(10):470–7.

19. Ren K, Dubner R. Interactions between the immune and nervous systems lead to pain. Nat Med. 2010;16(11):1267–76.

20. Djikgraff EM, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013;73(8):2480–92.

21. Miller RJ, Jung H, Bhangoo SK, White FA. Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol. 2009;194:417–49.

22. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, Ransohoff RM, Charo IF. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One. 2010;5(5):e10147.

23. Yuan F, Yosef N, Lakshmana Reddy C, Huang A, Chiang SC, Tithi HR, Ubogu EE. CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barre syndrome. PLoS One. 2014;9(4):e36.

24. Hansen N, Uçeyler N, Palm F, Zelenka M, Biko L, Lesch KP, Gerlach M, Sommer C. Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. Neurosci Lett. 2011;495(2):93–7.
25. Gao Y-J, Ji R-R. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? Open Pain J. 2009;2:11–7.
26. Bessler WK, et al. NF1+/- monocytes/macrophages induce neointima formulation via CCR2 activation. Hum Mol Genet. 2016;25(6):1129–39.
27. Sennlaub F, et al. CCR2 expressing monocytes infiltrate atrophic lesions in age-related macular disease and mediate photoreceptor degeneration in experimental subretinal inflammation in Cx3cr1 deficient mice. EMBO Mol Med. 2013; 5(11):1775–93.
28. Arnold L, et al. CX3CR1 deficiency promotes muscle repair and regeneration by enhancing macrophage ApoE production. Nat Commun. 2015;6:8972.
29. Binshtok AM, et al. Nociceptors are interleukin-1beta sensors. J Neurosci. 2008;28(52):14062–73.
30. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, Mack M, Charo IF. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest. 2007; 117(4):902–9.
31. Green SR, Han KH, Chen Y, Almazan F, Charo IF, Miller YL, Quehenberger O. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J Immunol. 2006;176(12):7412–20.
32. Van Steenwinckel J, Auvynet C, Sapienza A, Reaux-Le Goazigo A, Combadière C, Melik PS. Stromal cell-derived CCL2 drives neuropathic pain states through myeloid cell infiltration in injured nerve. Brain Behav Immun. 2015;45:198–210.
33. Zhu X, Cao S, Zhu MD, Liu JQ, Chen JJ, Gao YJ. Contribution of chemokine CCL2/CCR2 signaling in the dorsal root ganglion and spinal cord to the maintenance of neuropathic pain in a rat model of lumbar disc herniation. J Pain. 2014;15(5):516–26.
34. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci. 2009;29:4096–108.
35. Hensellek S, Brell P, Schäible HG, Bräuer R, Segond von Banchet G. The cytokine TNFalpha increases the proportion of DRG neurons expressing the TRPV1 receptor via the TNFR1 receptor and ERK activation. Mol Cell Neurosci. 2007;36(3):381–91.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit